PACT Pharma is developing tumor-mutation targeted T cells personalized for individual patients. The patient\’s T cells are programmed to seek the mutations on the patient\’s tumor and kill tumor cells. The endogenous receptors of fresh CD8 and CD4 T cells are replaced with mutation-targeted T cell receptors using DNA-mediated (non-viral) precision genome engineering. These \’native\’ tumor-targeted neoTCR-P1 T cells are then transferred back into the patient. Alex will describe PACT\’s DNA-mediated precision genome engineering and programming of fresh human cells utilizing novel approaches relevant to treating cancer and a spectrum of other diseases.

Biography:

Dr. Franzusoff joined PACT Pharma in 2017 to develop personalized adoptive T cell therapies using precision genome-engineered patient T cells that target confirmed tumor neoepitopes.